Adenoma - 647 Studies Found

Terminated : Long-term Cardiovascular Risk in Cured Cushing's Patients
: Cushing's Disease
: 2009-04-13
Not yet recruiting : Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition
: Iatrogenic Cushing's Disease
: 2017-03-17
:
  • Drug: AZD4017 and prednisolone

Completed : Cognition, Steroids, and Imaging in Cushings Disease
: Cushing Syndrome
: 2004-04-08
Completed : Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
:
  • Cushing's Disease
  • Corticotroph Adenoma : 2009-04-27
    : Drug: Cabergoline Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of
Completed : A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
: Cushing's Syndrome
: 2004-07-30
: Drug: SOM230 s.c.
Recruiting : Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
:
  • Pituitary Neoplasms
  • Prolactinoma
  • ACT
    : 2013-01-22
    : Other: Educational Intervention A brochure and access to a website including videos that contain detaile
Recruiting : Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
: Pituitary Neoplasm
: 2011-10-21
: Drug: Acthrel Ovine Corticorelin
Active, not recruiting : Rhinological Outcomes in Endonasal Pituitary Surgery
:
  • Pituitary Neoplasm
  • Pituitary Adenoma
  • Prolactinoma
    • : 2012-01-03
Recruiting : Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
:
  • Cushing's Disease
  • Acromegaly

  • : 2013-02-15
    : Drug: Pasireotide Pasireotide subcutaneous or Long Acting Release
Recruiting : Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
:
  • Pituitary Tumor
  • ACTH-producing Pituitary Tumour

: 2016-04-20
: Drug: Pasireotide LAR Pasireotide LAR (SIGNIFOR® LAR)
<<< Previous | Next >>>